Sirolimus-Induced Pulmonary Toxicity Without Recurrence More Than 8 Years After Everolimus Replacement in a Renal Transplant Patient With Recurrent Skin Scc: A Case Report Publisher Pubmed

Summary: Case report shows everolimus as a safe alternative to sirolimus for pulmonary toxicity in transplant patient. #Transplant #PulmonaryToxicity

Ghasemi G¹ ; Shahidi S²
Source: BMC Nephrology Published:2024

Abstract

Background: Interstitial Pneumonitis (IP) is one of the pulmonary complications associated with mammalian Target of Rapamycin-Inhibitors (mTOR-Is). Sirolimus and everolimus belong to mTOR-Is. According to studies, IP is caused by both. Case presentation: This is a case report in a kidney transplant recipient. We want to present a case of IP after 50 months of sirolimus consumption. Sirolimus was discontinued, and cyclosporine was started. Thirty-seven months later, everolimus was prescribed as an alternative to cyclosporine due to the recurrence of skin Squamous Cell Carcinoma (SCC). Fortunately, no respiratory manifestations were seen after more than 8 years of everolimus consumption. Conclusions: In conclusion, in cases with sirolimus-induced IP, discontinuation of sirolimus and replacement with everolimus are recommended after resolving clinical symptoms and pulmonary lesions. © The Author(s) 2024.